|Bioscience Valuation Team
Joachim M. Greuel, Ph.D., MBA
Managing Director, Co-Founder
Joachim earned his Ph.D. in Physiology 'Summa Cum Laude' from the Max-Planck-Institute for Brain Research in Frankfurt (Germany) and his MBA from the Wharton School of the University of Pennsylvania (USA). At the IE Business School in Madrid (Spain) he served as Academic Director and as Adjunct Professor of Finance and Healthcare Management, teaching the Business School's Pharmacoeconomics course. Besides, he is a certified stock broker / dealer (Frankfurt Stock Exchange).
Joachim began his professional career as head of a research team at Bayer AG (Germany). After his business education he joined the strategic services practice of Andersen Consulting (Switzerland and Germany). Before founding Bioscience Valuation Joachim was investment manager at New Medical Technologies, a Swiss venture capital fund.
Kerstin M. Bode-Greuel, MD, PhD.
Managing Director, Co-Founder
Kerstin studied Medicine in Marburg (Germany), Cambridge (UK) and Nottingham (UK). She started her professional career with a doctoral thesis in Neuroanatomy followed by a postdoc in Neurophysiology and Neuropharmacology at the Max-Planck-Institute for Brain Research (Frankfurt am Main, Germany). Subsequently Kerstin spent eight years at Bayer AG, holding several roles in R&D and responsibility as Global Program Manager for a clinical-stage product that has been developed in six indications. During that time she was also part of a corporate task force implementing value-driven portfolio management. Since 1995 Kerstin has been working as a consultant for the Pharma and Biotech industry. She was educated in Corporate Finance at the Wharton School of the University of Pennsylvania (USA) and developed and enhanced modern, quantitative project and portfolio management methods.
With the goal to expand her experience in evidence-based valuation taking advantage of patient-centric data, Kerstin worked for IQVIA 2012-2019. She developed new offerings for patient-based real world data and was Director of Business Development for Germany. During that time, she was also Managing Director of a Joint Venture between IQVIA and the Deutsches Institut for fachärztliche Versorgungsforschung, DIFA.
Senior Finance Consultant
Thomas studied economics at the Ludwig-Maximilian-University, Munich and graduated from the Executive MBA Program of Harvard Business School. Thomas started his professional career in 1984 as an investment banker at Klenner Securities Ltd. With a focus on NASDAQ-listed technology companies, he helped to build a small asset management company into a full-fledged US investment bank with UK and German subsidiaries and a focus on private placements, mezzanine financings and IPOs.
After joining the biotech industry in 1998, Thomas has served as CFO of several German, Swiss and US biotech companies, where he directed financial strategy and fundraising in USA and Europe. With a focus on building transatlantic businesses and brand name VC syndicates, his track record includes a series of M&A and trade sale exits that created both equity value and top quartile ROIs for the investors involved.
Sabine Bernotat-Danielowski, Ph.D., MBA
Director, Business Development
Sabine did her PhD thesis at the Max-Planck-Institute for Biophysics in Frankfurt (Germany) and continued her academic career at the Max-Planck-Institute for Experimental Cardiology (Bad Nauheim) before joining the pharmaceutical industry. She also earned an MBA from the Ashridge Management School (UK).
At Merck KGaA she advanced her career and leadership roles from discovery research, project management and clinical development to strategic marketing. With her broad experience in R&D Sabine became global Head Portfolio Planning and successfully implemented value-driven portfolio management. Her subsequent tenure at Daiichi Sankyo in the USA included a role as Head of the Business Analysis and Competitive Intelligence unit; during the merger of Daiichi and Sankyo she drove the design of an integrated R&D strategy and implementation of new business processes. More recently she became General Manager and Head of the Daiichi Sankyo Europe and India Drug Development organizations with responsibility from first-in-human studies to regulatory approval. Her particular interest is in end-to-end evidence based concepts ranging from a scientific idea to drug product attributes. Sabine served as member of the global executive R&D decision making committee.
Doug Morgan, Ph.D.
Douglas received a Ph.D. in Biochemistry from the University of Missouri-Columbia. He started his career in drug discovery at Hoffmann-LaRoche and advanced through positions at Abbott Laboratories, TAP Pharmaceuticals to become a Program Executive at Biogen Idec and most recently, a Senior Director in Clinical Development at Regeneron Pharmaceuticals. During his career, Douglas has designed drug development programs through NDA and he has led cross-corporate teams in successful discovery and clinical programs through IND submissions, early clinical development and Phase II proof-of-concept studies.
Doug was awarded academic research grants from the National Institutes of Health and the American Heart Association and has received awards from Abbott Laboratories and IPF Pharmaceuticals (Hannover, Germany) for his accomplishments in drug discovery.
Prof. Alexander Schuhmacher, Ph.D., MBA
Director, R&D Performance Metrics & Business Model Innovation
Alexander graduated in biology from the University of Constance (Germany) and in pharmaceutical medicine from Witten-Herdecke University (Germany); he is also a graduate of the Executive MBA program from the University of St. Gallen (Switzerland). As professor at Reutlingen University (Germany), Alexander teaches both business management and science. His research focus is on innovation management.
Prior to his academic career Alexander worked for 14 years in the pharmaceutical industry in various R&D positions. As member of Nycomeds senior management team, he headed the Strategic Planning & Business Support team and co-headed the R&D integration team following the merger of Nycomed and ALTANA Pharma. Alexander has in depth experience in R&D performance metrics, R&D efficiency and productivity measures, open innovation and business model innovation. In addition, he headed and coordinated various senior management committees and initiated strategic management and change management programs.
Thomas Zürcher, Ph.D.
Director, Southern Europe
Thomas graduated in molecular biology and biochemistry from the Swiss Federal Institute of Technology (ETH) of Zürich, and received his Ph.D. in immunology and virology from the University of Zürich. He then continued his scientific career as a Post-Doctoral Fellow at the Mount Sinai School of Medicine in New York (USA) and the National Center of Biotechnology in Madrid (Spain).
Thomas started his career at GlaxoWellcome and later as group and project leader at GlaxoSmithKline (UK), contributing significantly to the Relenza Program and the development of new HCV drugs. Subsequently he became the Scientific Director of Chimera Pharma (Madrid, Spain) leading the development of novel therapeutic and prophylactic vaccines. Most recently, Thomas served as CEO of Formune (Pamplona, Spain), a pioneering R&D Company dedicated to the development of therapeutic vaccines for the treatment of cancer and chronic infections.
Thomas has extensive know-how in directing and evaluating projects at the scientific and strategic levels across a variety of fields and technologies. He is particularly experienced in clinical development planning and IP management.
Philipp Steinbach, MS
Healthcare Financial & Business Analyst
Philipp studied Business Administration at the Frankfurt School of Finance & Management (Germany) and at the University College Dublin (Ireland) with a focus on financial mathematics, financial modelling, and international & corporate finance. In parallel to his Bachelor studies he worked at the Landesbank Hessen Thüringen in the fixed income trading sector.
After his Bachelor's degree Philipp did his Master's degree in Finance at the Leopold-Franzens University in Innsbruck (Austria) with a specialization in corporate evaluation. Philipp's responsibilities include financial modelling, portfolio assessments, as well as deal term valuations.
Engelbert Paschek, MS
Head, Economic Modeling
Engelbert studied technical mathematics in Innsbruck (Austria) and wrote his Masters thesis about the practical application of the concepts of game theory to the complex and dynamic decisions faced in competitive situations.
Since 2009 Engelbert has been supporting clients in all aspects of financial valuation, market forecasting, product and portfolio assessments and financial deal term analysis. He develops quantitative project and portfolio management tools, models to assess licensing opportunities as well as healthcare policies, and analyzes healthcare systems. He and his team also develops financial models and statistical methods to improve forecasting of a drug's sales potential and to evaluate public pharmaceutical and biotech companies. Engelbert has specific expertise in economic modeling, financial mathematics, valuation of stock options, and in the development of trading strategies.
Max Goller, BA
Healthcare Business Associate
Max began his higher education at the Technical University of Munich (Germany) with a Bachelor's degree in Health Sciences. To expand his knowledge in finance and economics he moved to Innsbruck (Austria) and completed his Bachelor in Health Management at the Management Center Innsbruck. He spent one semester at the Nagoya University of Commerce and Business (Japan) with a focus on financial valuation and accounting.
During his professional career, Max gained experience in Clinical Studies and R&D at MED-EL in Vienna and Innsbruck. Max is currently completing his extra-occupational Master's in International Business and Management with a focus in Financial Management.